Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma

Pier Luigi Zinzani, Lapo Alinari, Monica Tani, Mariapaola Fina, Stefano Pileri, Michele Baccarani

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

We assessed the impact of a reduced-dose (10 mg × 3/week for 4 weeks) schedule of alemtuzumab in 10 patients with pretreated cutaneous/peripheral T-cell lymphomas. The overall response rate was 60% (2 complete responses and 4 partial responses). In terms of infectious toxicity, cytomegalovirus reactivation occurred in 1 (10%) patient.

Original languageEnglish
Pages (from-to)702-703
Number of pages2
JournalHaematologica
Volume90
Issue number5
Publication statusPublished - May 2005

Fingerprint

T-Cell Lymphoma
Peripheral T-Cell Lymphoma
Cutaneous T-Cell Lymphoma
Cytomegalovirus
Appointments and Schedules
Therapeutics
alemtuzumab

Keywords

  • Alemtuzumab
  • CTCL
  • Low-dose
  • PTCL

ASJC Scopus subject areas

  • Hematology

Cite this

Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. / Zinzani, Pier Luigi; Alinari, Lapo; Tani, Monica; Fina, Mariapaola; Pileri, Stefano; Baccarani, Michele.

In: Haematologica, Vol. 90, No. 5, 05.2005, p. 702-703.

Research output: Contribution to journalArticle

Zinzani, Pier Luigi ; Alinari, Lapo ; Tani, Monica ; Fina, Mariapaola ; Pileri, Stefano ; Baccarani, Michele. / Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. In: Haematologica. 2005 ; Vol. 90, No. 5. pp. 702-703.
@article{9c43fa4a625e42d9a4742e374eed1300,
title = "Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma",
abstract = "We assessed the impact of a reduced-dose (10 mg × 3/week for 4 weeks) schedule of alemtuzumab in 10 patients with pretreated cutaneous/peripheral T-cell lymphomas. The overall response rate was 60{\%} (2 complete responses and 4 partial responses). In terms of infectious toxicity, cytomegalovirus reactivation occurred in 1 (10{\%}) patient.",
keywords = "Alemtuzumab, CTCL, Low-dose, PTCL",
author = "Zinzani, {Pier Luigi} and Lapo Alinari and Monica Tani and Mariapaola Fina and Stefano Pileri and Michele Baccarani",
year = "2005",
month = "5",
language = "English",
volume = "90",
pages = "702--703",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "5",

}

TY - JOUR

T1 - Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma

AU - Zinzani, Pier Luigi

AU - Alinari, Lapo

AU - Tani, Monica

AU - Fina, Mariapaola

AU - Pileri, Stefano

AU - Baccarani, Michele

PY - 2005/5

Y1 - 2005/5

N2 - We assessed the impact of a reduced-dose (10 mg × 3/week for 4 weeks) schedule of alemtuzumab in 10 patients with pretreated cutaneous/peripheral T-cell lymphomas. The overall response rate was 60% (2 complete responses and 4 partial responses). In terms of infectious toxicity, cytomegalovirus reactivation occurred in 1 (10%) patient.

AB - We assessed the impact of a reduced-dose (10 mg × 3/week for 4 weeks) schedule of alemtuzumab in 10 patients with pretreated cutaneous/peripheral T-cell lymphomas. The overall response rate was 60% (2 complete responses and 4 partial responses). In terms of infectious toxicity, cytomegalovirus reactivation occurred in 1 (10%) patient.

KW - Alemtuzumab

KW - CTCL

KW - Low-dose

KW - PTCL

UR - http://www.scopus.com/inward/record.url?scp=20344379951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344379951&partnerID=8YFLogxK

M3 - Article

C2 - 15921394

AN - SCOPUS:20344379951

VL - 90

SP - 702

EP - 703

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 5

ER -